



US Lacrosse Contact

Brian Logue
410-235-6882 x106
blogue@uslacrosse.org

Cardiac Science Contact

Mike Matysik
Chief Financial Officer
425-402-2009

Media Contact

EVC Group, Inc.
Steve DiMattia
646-201-5445

US Lacrosse and Cardiac Science Announce Strategic Alliance to Supply Lacrosse Programs with Powerheart AEDs

BOTHELL, WA and BALTIMORE – August 7, 2007 – Cardiac Science Corporation [NASDAQ: CSCX], a global leader in advanced cardiac monitoring and defibrillation products, and US Lacrosse, the national governing body for men’s and women’s lacrosse, announced today that they have formed a strategic alliance to increase the likelihood of surviving sudden cardiac arrest (SCA) during a lacrosse game. The alliance will accomplish this by increasing the awareness and availability of Powerheart® automated external defibrillators (AEDs) to US Lacrosse members and affiliated programs.

AEDs are an effective response to *commotio cordis*, a rare but potentially catastrophic phenomenon that can cause SCA in athletes. *Commotio cordis* occurs when a person receives a blunt blow to the area of the chest directly over the heart during a precise moment of the heart’s cycle, causing SCA. The blow need not be severe; in fact, *commotio cordis* can be caused by a relatively mild impact.

According to US Lacrosse, at least five lacrosse players are believed to have died during competition as a result of SCA caused by *commotio cordis* since 1999, though it has afflicted many more people in a variety of organized athletic events, recreational play and non-sports activities. The US Commotio Cordis Registry has received more than 180 reported cases of *commotio cordis* since it began keeping records in 1996. In addition to *commotio cordis*, US Lacrosse notes that other serious cardiac events have struck lacrosse coaches, officials, players and fans during competition.

“Lacrosse is the fastest-growing sport in the United States,” said Steve Stenersen, Executive Director of US Lacrosse. “Injury research shows that lacrosse is a relatively safe sport to play, but the risk of catastrophic injury still exists, as it does in every sport. In the rare case of a *commotio cordis* episode, or if SCA should afflict a spectator or official, the prompt and proper use of an AED greatly increases the odds of the victim’s survival. We encourage lacrosse organizations around the country to purchase AEDs as an additional step in the quest to provide the safest possible environment for their players, coaches, officials and spectators. This proactive step has the potential to save lives.”

As a result of the partnership, Cardiac Science will provide automated external defibrillators (AEDs) at preferred prices to members of US Lacrosse. The Company has also equipped the USL headquarters in Baltimore with an AED and is providing related training and program management services. Most importantly, the two organizations have committed to working together to achieve greater awareness of SCA and the importance of accessible defibrillation among the rapidly growing body of lacrosse players, coaches, officials and fans, nationwide.

“Tragically, many of us know of a friend or family member who has suffered an unexpected SCA,” said Mike Brode, Cardiac Science Director for Strategic Business. “We applaud US Lacrosse’s proactive step towards raising awareness of the value of having AEDs at the sidelines of its events across the country, ensuring that potentially life saving defibrillation is on-hand in case the unexpected should occur.”

For more information on AEDs and the partnership between U.S. Lacrosse and Cardiac Science, please visit www.uslacrosse.org/safety/aed.phtml or www.cardiacsciencepartners.com/USL/

About US Lacrosse

US Lacrosse, a 501(c)(3) corporation, is the national governing body for men’s and women’s lacrosse. To learn more about the organization, please visit the Web site at www.uslacrosse.org.

About Powerheart®

Powerheart brand automated external defibrillators provide reliable, safe, and easy to use cardiac monitoring and defibrillation technology. Powerheart AEDs feature RHYTHMx™ software which detects abnormal heart rhythms, determines whether they are life-threatening, and only delivers a shock when needed. Powerheart AEDs also feature the patented RescueReady® technology, which automatically tests the device on a frequent basis to ensure continued functionality. Powerheart’s STAR® Biphasic Waveform Technology provides levels of escalating energy customized to the patient. Powerheart AEDs are used by hospitals, police and fire departments, as well as many public access facilities including major corporations, public agencies, airlines and airports, arenas, schools, hotels, casinos and consumers. For more information about Powerheart, go to www.powerheart.com.

About Cardiac Science Corporation

Cardiac Science is truly at the heart of saving lives. The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor - defibrillators and cardiology data management systems. Cardiac Science also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The Company is the successor to various entities that have owned and operated cardiology-related businesses that sold products under the trusted brand names Burdick®, Powerheart®, and Quinton®. Cardiac Science is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin; Shanghai, China; Copenhagen, Denmark; and Manchester, United Kingdom.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include those that infer or imply that our alliances will enable us to be successful in the marketplace, and that our sales and profits derived from our AEDs and our other products will increase as a result. These statements, including their underlying assumptions, are subject to risks and uncertainties and are not guarantees of future performance. Results may differ due to various factors such as the possibility that the distribution relationship described in this release may be modified or terminated early; that the distribution partner may not generate sales of our AEDs to the extent expected; or that sales of our AEDs may fall short of projections due to unforeseen developments. Other risk factors that could cause or contribute to such varying results are described in our annual report for the year ended December 31, 2006, filed with the Securities and Exchange Commission.

The statements in this press release speak as of the date of the release, and Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

###